Literature DB >> 19058005

Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?

Gregory Kouraklis1, Iraklis E Katsoulis, Stamatios Theocharis, Gerasimos Tsourouflis, Nikos Xipolitas, Andromahi Glinavou, Chrysa Sioka, Alkiviadis Kostakis.   

Abstract

BACKGROUND: Cyclin E is a protein that plays a key role in the G1 --> S transition of the normal cell cycle. The product of retinoblastoma gene (pRb) is the master regulator of entry into the cell cycle and p21 protein is a cyclin-dependent kinase inhibitor that disturbs the progression through the cell cycle. The expression of these proteins, among many others, is being deregulated in tumorogenesis. The aim of this study was to investigate whether cyclin E, pRb, and p21 can be used as prognostic indicators in gastric cancer.
MATERIAL AND METHODS: Fifty-six patients with gastric adenocarcinoma, who underwent curative resection, constituted the group of our study. The immunohistochemical expression of cyclin E, pRb, and p21 proteins was examined and correlated with clinical-pathological parameters and survival.
RESULTS: Positive cyclin E immunostaining was observed in 23 tumors (41.1%). It was associated with intestinal Lauren classification (P=0.003), nodal infiltration (P=0.0025), size of the tumor >5 cm (P=0.032), and lymphatic (P=0.042) and vascular invasion (P= 0.0029). Nevertheless, the survival of patients with positive cyclin E tumors was not significantly shorter than that of negative patients. Positive pRb immunostaining was found in 24 (42.9%) cases and it was associated with the absence of Helicobacter pylori (P=0.044), whereas positive p21 immunostaining was found in 21 tumors (37.5%) and it was associated with less depth of gastric wall infiltration (P=0.001), the absence of lymphatic (P=0.019) and vascular infiltration (P=0.024), and the absence of liver metastasis (P=0.044). Cyclin E expression was associated with pRb expression (P=0.023), but was correlated inversely with p21 expression (P=0.009). The survival of patients with pRb-positive tumors and the survival of patients with p21-positive tumors were significantly longer than that of negative patients (P= 0.0044 and P<0.001, respectively).
CONCLUSION: The expression of cyclin E could not predict the survival in this series of patients with gastric cancer, whereas the expression of pRb and p21 was associated with a favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058005     DOI: 10.1007/s10620-008-0464-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  p21 expression is a prognostic factor in patients with p53-negative gastric cancer.

Authors:  C Xiangming; S Hokita; S Natsugoe; G Tanabe; M Baba; S Takao; K Kuroshima; T Aikou
Journal:  Cancer Lett       Date:  2000-02-01       Impact factor: 8.679

2.  Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival.

Authors:  V K Puduvalli; A P Kyritsis; K R Hess; M L Bondy; G N Fuller; G P Kouraklis; V A Levin; J M Bruner
Journal:  Int J Oncol       Date:  2000-11       Impact factor: 5.650

3.  A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.

Authors:  M Nakamura; M Katano; K Fujimoto; T Morisaki
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

4.  Loss of p16 and p27 is associated with progression of human gastric cancer.

Authors:  N Myung; M R Kim; I P Chung; H Kim; J J Jang
Journal:  Cancer Lett       Date:  2000-05-29       Impact factor: 8.679

5.  The loss of p27 protein has an independent prognostic significance in gastric cancer.

Authors:  O J Kwon; H S Kang; J S Suh; M S Chang; J J Jang; J K Chung
Journal:  Anticancer Res       Date:  1999 Sep-Oct       Impact factor: 2.480

6.  Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer.

Authors:  S J Jang; Y W Park; M H Park; J D Lee; Y Y Lee; T J Jung; I S Kim; I Y Choi; M Ki; B Y Choi; M J Ahn
Journal:  Eur J Surg Oncol       Date:  1999-04       Impact factor: 4.424

Review 7.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

8.  Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer.

Authors:  K Aoyagi; K Koufuji; S Yano; N Murakami; Y Terasaki; Y Yamasaki; J Takeda; M Tanaka; K Shirouzu
Journal:  Kurume Med J       Date:  2000

9.  Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival.

Authors:  Roger M Feakins; Carole D Nickols; Heena Bidd; Sarah-Jane Walton
Journal:  Hum Pathol       Date:  2003-12       Impact factor: 3.466

10.  Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma.

Authors:  M Ogawa; K Maeda; N Onoda; Y S Chung; M Sowa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  18 in total

1.  The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma.

Authors:  Alaattin Ozen; Zafer Kocak; Tammam Sipahi; Fulya Oz-Puyan; Suat Cakina; Mert Saynak; Cem Ibis; Hakan Karagol
Journal:  Med Oncol       Date:  2012-12-29       Impact factor: 3.064

2.  Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma.

Authors:  Jong-Shiaw Jin; Lien-Fu Lin; Jui-Chang Chen; Chia-Chi Huang; Jeng-Horng Sheu; Wenlung Chen; Tang-Yi Tsao; Chih-Wei Hsu
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

3.  Stem cell associated genes working with one miRNA cluster have different clinic pathologic values in gastric cancer.

Authors:  Qiong Wu; Zhiping Yang; Sijun Hu; Tao Su; Yanxin An; Zhiyong Zhang; Yongzhan Nie; Xin Wang; Yongquan Shi; Daiming Fan
Journal:  Pathol Oncol Res       Date:  2011-05-10       Impact factor: 3.201

Review 4.  Genomic and genetic alterations influence the progression of gastric cancer.

Authors:  Stefania Nobili; Lorenzo Bruno; Ida Landini; Cristina Napoli; Paolo Bechi; Francesco Tonelli; Carlos A Rubio; Enrico Mini; Gabriella Nesi
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

5.  The overexpression of AP-4 as a prognostic indicator for gastric carcinoma.

Authors:  Liu Xinghua; Zhang Bo; Guo Yan; Wu Lei; Wu Changyao; Liang Qi; Ye Lin; Tao Kaixiong; Wang Guobin; Chen Jianying
Journal:  Med Oncol       Date:  2011-02-20       Impact factor: 3.064

Review 6.  Pathogenetic mechanisms in gastric cancer.

Authors:  Jing Shi; Yi-Ping Qu; Peng Hou
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

7.  miR-449 inhibits cell proliferation and is down-regulated in gastric cancer.

Authors:  Tony Bou Kheir; Ewa Futoma-Kazmierczak; Anders Jacobsen; Anders Krogh; Linda Bardram; Christoffer Hother; Kirsten Grønbæk; Birgitte Federspiel; Anders H Lund; Lennart Friis-Hansen
Journal:  Mol Cancer       Date:  2011-03-18       Impact factor: 27.401

8.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

9.  A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer.

Authors:  Gayle Bennett; Denise Sadlier; Peter P Doran; Padraic Macmathuna; David W Murray
Journal:  BMC Cancer       Date:  2011-02-01       Impact factor: 4.430

10.  Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas.

Authors:  Xia Liu; Xiuming Tang; Shaoyan Zhang; Yun Wang; Xiaofeng Wang; Chengquan Zhao; Bing Luo
Journal:  Gastroenterol Res Pract       Date:  2012-09-12       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.